Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.

Experimental cell research - 15 Dec 2021

Nakagawa Nozomu, Miyake Noriko, Ochi Nobuaki, Yamane Hiromichi, Takeyama Masami, Nagasaki Yasunari, Ikeda Tomoko, Yokota Etsuko, Fukazawa Takuya, Nakanishi Hidekazu, Harada Daijiro, Kiura Katsuyuki, Takigawa Nagio

Abstract excerpt

Lung cancer that exhibits epidermal growth factor receptor (EGFR) gene mutation is sensitive to EGFR-tyrosine kinase inhibitors (TKIs), such as osimertinib. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) may be involved in overcoming EGFR-TKI resistance. Growth inhibition, colony formation, apoptosis, and mRNA/protein levels in four osimertinib-sensitive and resistant cell lines transfected with small...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Receptor Tyrosine Kinase-like Orphan Receptors

Share to RNA, Small Interfering

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 34808132
DOI: 10.1016/j.yexcr.2021.112940

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.PMID 34808132Read ↗

The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells.Semantic proximity Read ↗

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).Semantic proximity Read ↗

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.Semantic proximity Read ↗

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Raddeanin A Improves the Therapeutic Effect of Osimertinib in NSCLC by Accelerating ROS/NLRP3-mediated Pyroptosis.Semantic proximity Read ↗

Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both.Semantic proximity Read ↗

Targeting ROR1 identifies new treatment strategies in hematological cancersSemantic proximity Read ↗

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.Semantic proximity Read ↗

Gracillin overcomes osimertinib resistance in NSCLC via dual inhibition of EGFR and Mcl-1.Semantic proximity Read ↗

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Functional and Clinical Significance of Ror1 in Lung AdenocarcinomaSemantic proximity Read ↗

Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.